BiochemProbe — Life Science Research Reagents

Troriluzole free base

Troriluzole, a third-generation, tripeptide proagent of Riluzole , is an orally active glutamate modulator.

For research use only. Not for human or veterinary use.

Target mGluR
Purity >98% Stock Inquire

Troriluzole structure

CAS No.: 1926203-09-9

Download structure (.mol)

Pack sizes & pricing

Size Price SKU Stock
10 mg USD 365.00 BP-02418-10mg In stock Get quote
25 mg USD 730.00 BP-02418-25mg In stock Get quote
50 mg USD 1,170.00 BP-02418-50mg In stock Get quote
100 mg USD 1,870.00 BP-02418-100mg In stock Get quote
250 mg USD 3,740.00 BP-02418-250mg In stock Get quote
500 mg Inquire BP-02418-500mg In stock Inquire
1 g Inquire BP-02418-1g In stock Inquire

Need another size or custom synthesis? Request a quote.

Description

Troriluzole, a third-generation, tripeptide proagent of Riluzole , is an orally active glutamate modulator. Troriluzole reduces synaptic glutamate level and increases the synaptic glutamate absorption. Troriluzole has the potential for Alzheimer disease and generalized anxiety disorder (GAD) .

Biological activity

In Vitro Troriluzole is absorbed systemically and cleaves into riluzole by aminopeptidases.

Identifiers

SMILES
O=C(CN(C)C(CNC(CN)=O)=O)NC1=NC2=CC=C(OC(F)(F)F)C=C2S1
InChIKey
YBZSGIWIPOUSHY-UHFFFAOYSA-N

Specifications

MW (average)
419.3790
Formula
C15H16F3N5O4S
CAS No.
1926203-09-9
Physical state
Solid
Color
White to off-white
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage
Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month

Solubility

Soluble in DMSO : 50 mg/mL

References

[1].Schanzer B, et al. Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opin Investig Drugs. 2019 Nov;28(11):1003-1012.
[2].Huang LK, et al. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020 Jan 6;27(1):18.